CIVCO Radiotherapy is involved in the designing and manufacturing of radiotherapy patient positioning and immobilisation devices
Blue Wolf Capital has agreed to acquire CIVCO Radiotherapy. (Credit: Michal Jarmoluk from Pixabay)
New York-based private equity company Blue Wolf Capital Partners has agreed to acquire CIVCO Radiotherapy from Roper Technologies for an undisclosed sum.
Established in 1982, CIVCO Radiotherapy is involved in the designing and manufacturing of radiotherapy patient positioning and immobilisation devices.
The company’s devices are said to help deliver safe cancer treatment to patients.
Founded in 1982, CIVCO supplies its products to academic and community hospitals, cancer centres and original equipment manufacturer (OEM) manufacturers.
With around 115 employees, CIVCO carries out operations in more than 90 countries across the globe.
The company has its headquarters and production facilities in Iowa.
CIVCO Radiotherapy current president Nat Geissel said: “We are pleased to have found a trusted partner in Blue Wolf with the skills, expertise and capital to support our significant growth goals and mission of improving outcomes for patients and healthcare providers worldwide.
“Blue Wolf has a track record of successfully managing businesses. I’m confident their team will help to enhance our production capabilities and distribution efficiencies to meet the needs of patients and healthcare providers globally.”
Upon completion of the deal, Geissel will be appointed as the CEO of the company.
Blue Wolf Capital principal Shashank Patel said: “The company has a rich history of improving the patient experience and clinical outcomes for cancer patients globally. We believe CIVCO Radiotherapy is well positioned to further help clinicians offer more targeted and accurate treatment to patients as innovations in the radiotherapy space continue.”
The deal is expected to be completed by the end of this year.